Related Experiment Video
Updated: Apr 12, 2026
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases
Stefan Tukaj1, Detlef Zillikens1, Michael Kasperkiewicz1
1Department of Dermatology, University of Lübeck, Lübeck, Germany.
Abstract:
The chaperone heat shock protein 90 (Hsp90), a cell stress-inducible molecule that regulates activity of many client proteins responsible for cellular growth, differentiation and apoptosis, has been proposed as an important therapeutic target in patients with malignancies. More recently, its active participation in (auto)immune processes has been recognized as evidenced by amelioration of inflammatory disease pathways through pharmacological inhibition of Hsp90 in rodent models of autoimmune encephalomyelitis, rheumatoid arthritis and systemic lupus erythematosus. Based on own current research results, this viewpoint essay provides important insights that Hsp90 is also involved as a notable pathophysiological factor in autoimmune blistering dermatoses including epidermolysis bullosa acquisita, bullous pemphigoid and possibly dermatitis herpetiformis. The observed in vitro, ex vivo and in vivo efficacy of anti-Hsp90 treatment in experimental models of autoimmune bullous diseases and its underlying multimodal anti-inflammatory mechanisms of interference with key contributors to autoimmune-mediated blister formation supports the introduction of selective non-toxic Hsp90 inhibitors into the clinical setting for the treatment of patients with these disorders.
Insights
Heat shock protein 90 (Hsp90) is a therapeutic target for cancer and autoimmune diseases. New research shows Hsp90 inhibition effectively treats experimental autoimmune blistering skin diseases.
Area of Science:
- Immunology
- Dermatology
- Molecular Biology
Background:
- Heat shock protein 90 (Hsp90) is a crucial chaperone protein involved in cellular growth, differentiation, and apoptosis.
- Hsp90 plays a role in regulating the activity of numerous client proteins.
- Recent studies highlight Hsp90's involvement in autoimmune processes, with inhibition ameliorating inflammatory pathways in models of autoimmune encephalomyelitis, rheumatoid arthritis, and systemic lupus erythematosus.
Purpose of the Study:
- To investigate the role of Hsp90 as a pathophysiological factor in autoimmune blistering dermatoses.
- To evaluate the efficacy of anti-Hsp90 treatment in experimental models of autoimmune bullous diseases.
- To elucidate the anti-inflammatory mechanisms underlying Hsp90 inhibition in these conditions.
Main Methods:
- In vitro, ex vivo, and in vivo studies were conducted using experimental models of autoimmune blistering dermatoses.
- Pharmacological inhibition of Hsp90 was employed as a therapeutic strategy.
- Analysis of underlying anti-inflammatory mechanisms of Hsp90 interference with key contributors to autoimmune-mediated blister formation.
Main Results:
- Heat shock protein 90 (Hsp90) is implicated as a significant factor in the pathophysiology of autoimmune blistering dermatoses, including epidermolysis bullosa acquisita and bullous pemphigoid.
- Anti-Hsp90 treatment demonstrated efficacy in experimental models of these autoimmune skin disorders.
- Multimodal anti-inflammatory mechanisms were identified, interfering with key pathways driving autoimmune-mediated blister formation.
Conclusions:
- Hsp90 is a notable pathophysiological factor in autoimmune blistering dermatoses.
- Targeting Hsp90 with selective, non-toxic inhibitors shows promise for treating these conditions.
- Clinical introduction of Hsp90 inhibitors is supported for patients suffering from autoimmune bullous disorders.
Related Concept Videos
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
01:26Bacterial Protein Maturation